All
Dermatology Times Spot Test: May 17, 2025
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!
Daily Derm Times: May 16, 2025
Catch up on dermatology news, highlights, and insights from the past 24 hours.
Psoriasis and Cellulitis Burden Has Increased in the US, According to New Posters
Recent posters at SID revealed significant increases in psoriasis and cellulitis cases in the US, highlighting urgent needs for prevention and treatment strategies.
The Skin Cancer Foundation Raises $800,000 at Annual Champions for Change Gala
The Skin Cancer Foundation's gala raises over $800,000, featuring Christie Brinkley and highlighting vital skin cancer awareness initiatives and personal stories.
Transforming Risk Stratification in Melanoma and Squamous Cell Carcinoma
Integrating molecular testing into melanoma and SCC management enhances risk assessment and personalizes treatment, revolutionizing patient care in dermatology.
Evidence Highlights Thiamidol’s Efficacy and Safety in Hyperpigmentation Treatment
Thiamidol emerges as a promising treatment for hyperpigmentation, showcasing superior efficacy and safety compared to traditional options like hydroquinone.
Q&A: Laura Scott, MD, FAAD, and Sun Bum on the Road to Accessible Sun Safety
Sun safety awareness grows with Laura Scott, MD, FAAD, and Sun Bum's "Trust the Bum Tour," offering free SPF products and education to diverse communities nationwide.
GLP-1 Therapy Offers Dual Benefits for Skin and Heart
GLP-1 receptor agonists show promise in reducing cardiovascular risks for patients with chronic inflammatory skin diseases like psoriasis and atopic dermatitis.
FDA Approves Sun Pharma's New LED BLU-U Device for AK
Sun Pharma's innovative BLU-U device gains FDA approval, revolutionizing actinic keratosis treatment with advanced blue light therapy.
New Antiaging Senotherapeutics: Senolytics and Senomorphics
Explore the latest advancements in senotherapeutics, targeting aging through senolytics and senomorphics for enhanced skin health and healing.
Daily Derm Times: May 15, 2025
New Guidance Aims to Improve Genital Psoriasis Treatment
New guidelines from the Genital Psoriasis Wellness Consortium highlight the significant impact of genital psoriasis on patients, emphasizing improved diagnosis and personalized treatment.
IL-23 and IL-17 Inhibitors Reduce Cardiovascular Outcomes in Statin-Treated Psoriasis Patients
Biologics significantly lower cardiovascular risks in psoriasis patients on statins, highlighting their dual benefits for skin and heart health.
Lurie Children’s Becomes First Treatment Center for Zevaskyn Gene Therapy in Patients with RDEB
ZEVASKYN, the first FDA-approved gene therapy for wounds in recessive dystrophic epidermolysis bullosa, is now available at Lurie Children's Hospital.
Artax Biopharma's AX-158: A Novel Approach to T Cell-Driven Inflammation in Psoriasis
Scott Batty, MD, and Chris VanDeusen, PhD, provided insights on AX-158's phase 2a results, presented at the SID Annual Meeting.
Risankizumab Effective in Difficult-to-Treat Psoriasis Areas
Discover the promising results of risankizumab for treating genital and scalp psoriasis, showcasing significant improvements in symptoms and quality of life.
Practice and Personal Planning: Tactics That Reduce Taxes and Protect Assets
Explore effective tax and asset protection strategies for dermatologists, including retirement plans and life insurance options for wealth management.
Daily Derm Times: May 14, 2025
Recludix Unveils First BTK SH2 Domain Inhibitor
Recludix Pharma unveils a groundbreaking BTK SH2 inhibitor, showcasing superior selectivity and efficacy for chronic spontaneous urticaria treatment at SID 2025.
AbbVie and ADARx Join Forces to Advance Next-Generation siRNA Therapies
The new partnership brings RNA-targeted innovation to dermatology-relevant disease areas like autoimmunity and cancer.
Quoin Announces Positive QRX003 Data for Pediatric Peeling Skin Syndrome
A pediatric patient with Peeling Skin Syndrome observed overall skin healing with no adverse events after 12 weeks of treatment.
UVB Phototherapy and Tofacitinib Are Effective for Combined Vitiligo Treatment
Combining tofacitinib with UVB therapy significantly enhances vitiligo treatment outcomes, improving recovery rates and quality of life for patients.
Clinuvel Completes Enrollment in Phase III Afamelanotide Vitiligo Trial
Clinuvel's phase III trial CUV105 enrolls 200 patients, exploring afamelanotide as a promising systemic treatment for vitiligo.
Prolonged Use of Oral Corticosteroids in Atopic Dermatitis Linked to Increased Cardiovascular Risks
Extended oral corticosteroid therapy in patients with atopic dermatitis significantly increases cardiovascular and thrombotic risks, urging careful treatment evaluations.
Toughness Is More Than Skin-Deep: Who Cries and Who Doesn’t in a Dermatology Clinic
Hershel Dobkin, MD, FAAD, discusses the surprising truth about toughness in dermatology, unexpected patient reactions, and the emotional depth behind appearances.
Journal Digest: May 14
This review of the latest dermatologic studies includes insights into switching PD-1 to BRAF + MEK inhibition, clinical outcomes and prognosis in atypical fibroxanthoma, and more.
Daily Derm Times: May 13, 2025
Tyk2 Inhibition Prevents Islet Inflammation and Delays Type 1 Diabetes Development in Mice
New research reveals a promising strategy to slow type 1 diabetes progression by targeting inflammation with an existing psoriasis drug.
Dual Inhibitor TRIV-509 Shows Promise for Rapid Improvement in Atopic Dermatitis
Researchers reveal TRIV-509, a novel monoclonal antibody, shows promise in rapidly improving atopic dermatitis by restoring skin barrier integrity and reducing inflammation.
Botanical-Based Nutraceutical Improves Acne
Discover how a novel nutraceutical significantly improves mild to moderate acne in a 12-week clinical trial, offering a holistic approach to skin health.
